Results 111 to 120 of about 2,469,529 (358)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. [PDF]

, 2018
Our expanding knowledge of immunotherapy for solid tumors has led to an explosion of clinical trials aimed at urothelial carcinoma. The primary strategy is centered on unleashing the immune system by releasing the inhibitory signals propagated by ...
Chamie, Karim, Crosetti, Anna M, Cummings, Amy L, Drakaki, Alexandra, Faiena, Izak, Pantuck, Allan J   +5 more
core   +1 more source

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys [PDF]

, 2013
Human immunodeficiency virus type 1 (HIV-1)-specific monoclonal antibodies with extraordinary potency and breadth have recently been described. In humanized mice, combinations of monoclonal antibodies have been shown to suppress viraemia, but the ...
Barouch, Dan H., Beck, Matthew, Blackmore, Stephen, Borducchi, Erica N., Burton, Dennis R., Cabral, Crystal, Chakraborty, Arup K., Chang, Hui-Wen, Gupta, Sanjana, Klein, Florian, Lewis, Mark G., Liu, Jinyan, Moldt, Brian, Nkolola, Joseph P., Nussenzweig, Michel C., Oliveira, Thiago Y., Perry, James R., Poignard, Pascal, Rinaldi, William, Sanisetty, Srisowmya, Seaman, Michael S., Shekhar, Karthik, Smith, Jeffrey Y., Smith, Kaitlin M., Stephenson, Kathryn E., Whitney, James B.   +25 more
core   +3 more sources

Fixed Dosing of Monoclonal Antibodies in Oncology

The Oncologist, 2017
In the field of oncology, most drugs are administered in a body–size‐based dosing schedule instead of a fixed dose for all patients. This article presents the advantages of fixed dosing of monoclonal antibodies, arguing in favor of fixed dosing schemes ...
J. Hendrikx, J. Haanen, E. Voest, J. Schellens, A. Huitema, J. Beijnen   +5 more
semanticscholar   +1 more source

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Science, 2020
Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al.
P. Brouwer, Tom G. Caniels, K. van der Straten, Jonne L. Snitselaar, Y. Aldon, S. Bangaru, J. Torres, Nisreen M. A. Okba, M. Claireaux, G. Kerster, A. Bentlage, M. M. van Haaren, Denise Guerra, J. Burger, Edith E. Schermer, K. Verheul, N. van der Velde, Alex van der Kooi, J. van Schooten, M. V. van Breemen, Tom P. L. Bijl, Kwinten Sliepen, A. Aartse, R. Derking, I. Bontjer, N. Kootstra, W. Wiersinga, G. Vidarsson, B. Haagmans, A. Ward, G. D. de Bree, R. Sanders, M. V. van Gils   +32 more
semanticscholar   +1 more source

Targeted protein degradation in oncology: novel therapeutic opportunity for solid tumours?

Molecular Oncology, EarlyView.
Current anticancer therapies are limited by the occurrence of resistance and undruggability of most proteins. Targeted protein degraders are novel, promising agents that trigger the selective degradation of previously undruggable proteins through the recruitment of the ubiquitin–proteasome machinery. Their mechanism of action raises exciting challenges,
Noé Herbel, Sophie Postel‐Vinay
wiley   +1 more source

OBTAINING OF MONOCLONAL ANTIBODIES AGAINST CHOLERA TOXIN AND HEAT LABILE ENTEROTOXIN OF E. coli FOR DEVELOPMENT OF THE TOXINS DIPLEX ANALYSIS IN ENVIRONMENTAL SPECIMENS [PDF]

Biotechnologia Acta, 2013
The present study focuses on development of monoclonal antibodies (MAbs) which specifically interact with cholera toxin or heat labile enterotoxin of E. coli.
Eu. V. Grishin, T. I. Valiakina
doaj   +1 more source

How is the Monoclonal Antibodies Kinetic Affected by Changes of Their Physical Parameters? [PDF]

arXiv, 2010
The study of monoclonal antibodies (MAb) is a field of great interest to science medicine, for example, anti-TNF agents (infliximab and adalimumab) represent an important tool for the management of autoimmune and inflammatory disorders. In this work we focus on the physical description of the transport kinetics of MAb in a fluid with laminar flow and ...
arxiv  

Monoclonal antibodies to the cells of a regenerating limb [PDF]

, 1985
Monoclonal antibodies were raised against differentiated cells, and blastemal cells from regenerating limbs of adult newts (Notophthalmus viridescens) and screened for specific staining by immunocytochemistry.
Brockes, Jeremy P., Kintner, Chris R.
core  

From rabbit antibody repertoires to rabbit monoclonal antibodies

Experimental &Molecular Medicine, 2017
In this review, we explain why and how rabbit monoclonal antibodies have become outstanding reagents for laboratory research and increasingly for diagnostic and therapeutic applications.
Justus Weber, Haiyong Peng, C. Rader
semanticscholar   +1 more source

Aberrant expression of nuclear prothymosin α contributes to epithelial‐mesenchymal transition in lung cancer

Molecular Oncology, EarlyView.
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen, Chung‐Teng Wang, Jia‐Ming Chang, Ai‐Li Shiau, Gia‐Shing Shieh, Yau‐Lin Tseng, Yi‐Ting Yen, Tang‐Hsiu Huang, Li‐Hsin Cheng, Yu‐Chih Wu, Chao‐Liang Wu, Bing‐Hua Su, Pensee Wu   +12 more
wiley   +1 more source